Sign in

Christopher Lu

Research Analyst at SVB Leerink

Christopher Lu is a Research Analyst at SVB Leerink specializing in biopharmaceutical equity research with a focus on clinical-stage companies. He has covered firms such as HOOKIPA Pharma and Pharvaris NV, with records showing active participation in earnings calls and initiating coverage with Outperform ratings. Lu began his analyst career in the early 2020s and has since established himself within SVB Leerink’s healthcare research team, though prior professional experience and additional firm history are not publicly documented. His FINRA registration and securities licenses, as well as notable performance rankings or award recognitions, are not detailed in available sources.

Christopher Lu's questions to HOOKIPA Pharma (HOOK) leadership

Question · Q4 2020

Christopher Lu of SVB Leerink inquired about the upcoming AACR presentation, asking if preliminary efficacy data for the alternating dose regimen would be shared, how to interpret the read-through from immunogenicity to efficacy, and if multiple clinical updates for the alternating regimen were planned.

Answer

Igor Matushansky, Chief Medical Officer, clarified that the AACR presentation will focus exclusively on translational data, with clinical efficacy updates reserved for the ASCO conference in June. He explained that based on preclinical data, improved immunogenicity is expected to translate to improved efficacy. Matushansky confirmed that clinical efficacy for both the HB-201 and HB-201/HB-202 programs would be updated at ASCO.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts